Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).

Autor: de Haas SL; Oncology Biomarker Development, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland. sanne_lysbet.de_haas@roche.com., Slamon DJ; Division of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Martin M; Medical Oncology Service, Hospital Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain., Press MF; Department of Pathology, Keck School of Medicine, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA., Lewis GD; Discovery Oncology, Genentech, Inc., South San Francisco, CA, USA., Lambertini C; Oncology Biomarker Development, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland., Prat A; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.; Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain., Lopez-Valverde V; Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Boulet T; Product Development Biometrics Biostatistics, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Hurvitz SA; Division of Hematology-Oncology, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.

Publikováno v: Breast cancer research : BCR [Breast Cancer Res] 2023 Jan 11; Vol. 25 (1), pp. 2. Date of Electronic Publication: 2023 Jan 11.

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.

Autor: Harbeck N; Breast Center, Department of Obstetrics and Gynecology and CCCLMU, University of Munich (LMU), Marchioninistrasse 15, 81377 Munich, Germany.; The West German Study Group, 41061 Mönchengladbach, Germany., von Schumann R; Evangelical Hospital Bethesda, 41061 Mönchengladbach, Germany., Kates RE; The West German Study Group, 41061 Mönchengladbach, Germany., Braun M; Red Cross Hospital, 80634 Munich, Germany., Kuemmel S; Evangelical Hospital Bethesda, 41061 Mönchengladbach, Germany.; Breast Unit, Kliniken Essen-Mitte, 45136 Essen, Germany.; Klinik für Gynäkologie mit Brustzentrum Charité-Universitätsmedizin, 10117 Berlin, Germany., Schumacher C; St Elisabeth-Krankenhaus, 50935 Cologne, Germany., Potenberg J; Evangelischen Waldkrankenhaus Spandau, 13589 Berlin, Germany., Malter W; Breast Center, Department of Obstetrics and Gynecology, University Hospital Cologne, 50937 Cologne, Germany., Augustin D; Breast Center, Clinic Deggendorf, 94469 Deggendorf, Germany., Aktas B; University of Essen, 45147 Essen, Germany., Forstbauer H; Onkologie Rheinsieg, 53840 Troisdorf, Germany., Tio J; University Hospital Münster, 48149 Münster, Germany., Grischke EM; University Hospital of Tübingen, 72076 Tübingen, Germany., Biehl C; Westphalian Breast Center, City Hospital Dortmund, 44137 Dortmund, Germany., Liedtke C; University of Lübeck, 23562 Lübeck, Germany., De Haas SL; F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland., Deurloo R; F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland., Wuerstlein R; Breast Center, Department of Obstetrics and Gynecology and CCCLMU, University of Munich (LMU), Marchioninistrasse 15, 81377 Munich, Germany., Kreipe HH; Hannover Medical School, 30625 Hannover, Germany., Gluz O; The West German Study Group, 41061 Mönchengladbach, Germany.; Evangelical Hospital Bethesda, 41061 Mönchengladbach, Germany.; Breast Center, Department of Obstetrics and Gynecology, University Hospital Cologne, 50937 Cologne, Germany.

Publikováno v: Cancers [Cancers (Basel)] 2021 Sep 29; Vol. 13 (19). Date of Electronic Publication: 2021 Sep 29.

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.

Autor: Emens LA; University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, USA. Electronic address: emensla@upmc.edu., Esteva FJ; Perlmutter Cancer Center at New York University Langone Health, New York, NY, USA., Beresford M; Royal United Hospital, Bath, UK., Saura C; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain., De Laurentiis M; Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy., Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea., Wang Y; Roche (China) Holding, Shanghai, China., Salgado R; Department of Pathology, Gasthuis Zusters Antwerpen-Ziekenhuis Netwerk Antwerpen Hospitals, Antwerp, Belgium., Mani A; Genentech, South San Francisco, CA, USA., Shah J; Genentech, South San Francisco, CA, USA., Lambertini C; F Hoffmann-La Roche, Basel, Switzerland., Liu H; Genentech, South San Francisco, CA, USA., de Haas SL; F Hoffmann-La Roche, Basel, Switzerland., Patre M; F Hoffmann-La Roche, Basel, Switzerland., Loi S; Division of Research, Peter MacCallum Cancer Center, Melbourne, VIC, Australia. Electronic address: sherene.loi@petermac.org.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2020 Oct; Vol. 21 (10), pp. 1283-1295.

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

Autor: Shah MA; Division of Hematology and Medical Oncology, Meyer Cancer Center of Weill Cornell Medical College, New York, NY, USA. mas9313@med.cornell.edu.; Solid Tumor Service, Gastrointestinal Oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, 1305 York Avenue, New York, NY, 10021, USA. mas9313@med.cornell.edu., Kang YK; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Thuss-Patience PC; Department of Hematology, Oncology and Tumor Immunology, Charité - University Medicine Berlin, Berlin, Germany., Ohtsu A; Department of GI Oncology/Gastroenterology, National Cancer Center Hospital East, Kashiwa, Japan., Ajani JA; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Van Cutsem E; Digestive Oncology, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium., Hoersch S; Statistics Department, KOEHLER eClinical GmbH, Freiburg, Germany., Harle-Yge ML; Pharmaceutical Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland., de Haas SL; Department of Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Publikováno v: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Gastric Cancer] 2019 Jul; Vol. 22 (4), pp. 803-816. Date of Electronic Publication: 2019 Jan 31.

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Autor: Perez EA; Mayo Clinic, 4500 San Pablo Rd. S, Jacksonville, FL, 32224, USA. Perez.edith@mayo.edu., de Haas SL; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland., Eiermann W; Interdisciplinary Oncology Center, Nussbaumstrasse 12, 80336, Munich, Germany., Barrios CH; PUCRS School of Medicine, Av. Ipiranga 6681, Porto Alegre, RS, 90619-900, Brazil., Toi M; Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan., Im YH; Samsung Medical Centre, 81 Irwon-Ro Gangnam-gu, Seoul, 06351, South Korea., Conte PF; Department of Surgery, Oncology and Gastroenterology, University of Padova and Istituto Oncologico Veneto, Via Gattamelata 64, 35128, Padova, Italy., Martin M; Instituto de Investigacion Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Avda. de Séneca, 2, 28040, Madrid, Spain., Pienkowski T; Postgraduate Medical Education Center, ul. Marymoncka 99, 02-813, Warsaw, Poland., Pivot XB; Paul Strauss Cancer Center, 3 Rue de la Porte de l'Hôpital, BP 30042-67065, Strasbourg, France., Burris HA 3rd; Sarah Cannon Research Institute and Tennessee Oncology, PLLC, 250 25th Ave N, Nashville, TN, 37203, USA., Stanzel S; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland., Patre M; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland., Ellis PA; Guys Hospital and Sarah Cannon Research Institute, Great Maze Pond, London, SE1 9RT, UK.

Publikováno v: BMC cancer [BMC Cancer] 2019 May 30; Vol. 19 (1), pp. 517. Date of Electronic Publication: 2019 May 30.